Tamoxifen citrate was originally created in 1962 by Imperial Chemical Industries (ICI) with studies focusing on its potential, in treating infertility before gaining approval from the FDA, for breast cancer treatment in 1977. Marketed under the name Nolvadex, tamoxifen became widely available, with its manufacturer eventually becoming AstraZeneca. The focus, on tamoxifen increased following the discovery of the link between estrogen and breast cancer. Trials involving the use of tamoxifen, in breast cancer patients started in 1971. Tamoxifen's role expanded in 1998 when the FDA approved its use for breast cancer prevention in high-risk women Today it stands out as one of the choices, among athletes and bodybuilders, for its ability to block estrogen effectively.

References:

Llewellyn, W. (2017). William Llewellyn's Anabolics.
United States: Molecular Nutrition, LLC.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For more details consult with your doctor or healthcare professional.

FAQ

What is Tamoxifen Citrate?

Tamoxifen citrate is a type of medication that selectively blocks estrogen receptors and is recognized for its ability to block estrogen in tissues while mimicking estrogen in others, commonly employed in the treatment of breast cancer.

References:

Llewellyn, W. (2017). William Llewellyn's Anabolics.
United States: Molecular Nutrition, LLC.

Who developed Tamoxifen Citrate?

Tamoxifen citrate was first synthesized by Imperial Chemical Industries (ICI) in 1962.

References:

Llewellyn, W. (2017). William Llewellyn's Anabolics.
United States: Molecular Nutrition, LLC.

What was the original purpose of Tamoxifen Citrate?

It was initially developed to treat female infertility, although this was not its most effective use.

References:

Llewellyn, W. (2017). William Llewellyn's Anabolics.
United States: Molecular Nutrition, LLC.